Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May 13;9(1):7259.
doi: 10.1038/s41598-019-43541-8.

First Report of Prevalence of Blood-Borne Viruses (HBV, HCV, HIV, HTLV-1 and Parvovirus B19) Among Hemophilia Patients in Afghanistan

Affiliations

First Report of Prevalence of Blood-Borne Viruses (HBV, HCV, HIV, HTLV-1 and Parvovirus B19) Among Hemophilia Patients in Afghanistan

Sayed Hamid Mousavi et al. Sci Rep. .

Abstract

Blood-borne viruses including Hepatitis B and C, HIV, HTLV-1 and parvovirus B19 are still a factor of concern, especially for hemophilia patients. Although the safety of the blood supply continues to improve worldwide, the blood supply system in Afghanistan was damaged by many years of conflict and political instability. To date, there are few studies focused on the prevalence of blood-borne viruses in hemophilia patients. This study is first to investigate the prevalence of five blood-borne viruses in Afghanistan hemophilia patients in four cities including Kabul, Herat, Mazar-i-Sharif and Jalal Abad. A total of 80 hemophilia male patients were screening for the presence of five transfusion-transmitted viruses using ELISA and PCR. Data obtained showed 2.5% seropositivity for HBV, 8.75% seropositivity for HCV, and 91.25% seropositivity for parvovirus B19. None of the patients were positive for HIV and HTLV-1 and the prevalence of HCV was higher in older patients rather than younger patients. This finding, the first to report in Afghanistan, shows a high prevalence of parvovirus B19 in Afghanistan hemophilia patients and implementation of highly sensitive screening is necessary.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

References

    1. Mannucci PM, Tuddenham EG. The hemophilias—from royal genes to gene therapy. New England Journal of Medicine. 2001;344:1773–1779. doi: 10.1056/NEJM200106073442307. - DOI - PubMed
    1. Konkle, B., Josephson, N. & Nakaya Fletcher, S. Hemophilia A. 2000 Sep 21 [Updated 2014 Jun 5]. GeneReviewsâ [Internet]. Seattle (WA): University of Washington, Seattle2014 (1993).
    1. Zimmerman B, Valentino LA. Hemophilia: in review. Pediatr Rev. 2013;34:289–294. doi: 10.1542/pir.34-7-289. - DOI - PubMed
    1. Mannucci PM. Hemophilia: treatment options in the twenty‐first century. Journal of Thrombosis and Haemostasis. 2003;1:1349–1355. doi: 10.1046/j.1538-7836.2003.00262.x. - DOI - PubMed
    1. Pipe SW. Recombinant clotting factors. Thrombosis And Haemostasis-Stuttgart- 2008;99:840. doi: 10.1160/TH07-10-0593. - DOI - PubMed

Publication types

MeSH terms